Tao Xiao, Jing Zheng Wen, Yuan Wang Kui, Yun Guo Hui, Fang Xie Jian, Sheng Liao Ming
Department of Psychiatry, The Third People's Hospital of Ganzhou, Ganzhou, Jiangxi, China.
Front Psychiatry. 2025 Feb 3;15:1504727. doi: 10.3389/fpsyt.2024.1504727. eCollection 2024.
This study compares the safety and effectiveness of theta-burst stimulation (TBS) and repetitive transcranial magnetic stimulation (rTMS) for treating treatment-resistant depression (TRD).
We reviewed randomized controlled trials (RCTs) that evaluated rTMS and TBS in managing TRD. Searches were conducted in PubMed, Embase, the Cochrane Library, and Web of Science for studies published up to July 31, 2024. Data from these studies were analyzed using statistical software.
Five RCTs involving 1,196 patients were included, with 553 receiving rTMS and 663 receiving TBS. The analysis found no significant differences between rTMS and TBS in reducing depression [SMD = -0.07, 95% CI (-0.19, 0.04)] or anxiety [SMD = -0.02, 95% CI (-0.15, 0.11)], nor in side effects like headaches [OR = 1.00, 95% CI (0.72, 1.40)], nausea [OR = 1.42, 95% CI (0.79, 2.54)], or fatigue [OR = 0.87, 95% CI (0.46, 1.64)].
Both rTMS and TBS are similarly effective in reducing depression and anxiety symptoms, with comparable side effect profiles. However, TBS is more time-efficient, with sessions lasting only 192 seconds, making it a cost-effective option for patients. These findings support TBS as a practical treatment choice for TRD.
本研究比较了theta爆发刺激(TBS)和重复经颅磁刺激(rTMS)治疗难治性抑郁症(TRD)的安全性和有效性。
我们回顾了评估rTMS和TBS治疗TRD的随机对照试验(RCT)。在PubMed、Embase、Cochrane图书馆和科学网中检索截至2024年7月31日发表的研究。使用统计软件对这些研究的数据进行分析。
纳入了5项涉及1196例患者的RCT,其中553例接受rTMS,663例接受TBS。分析发现,rTMS和TBS在减轻抑郁[标准化均数差(SMD)=-0.07,95%置信区间(CI)(-0.19,0.04)]或焦虑[SMD=-0.02,95%CI(-0.15,0.11)]方面无显著差异,在头痛[比值比(OR)=1.00,95%CI(0.72,1.40)]、恶心[OR=1.42,95%CI(0.79,2.54)]或疲劳[OR=0.87,95%CI(0.46,1.64)]等副作用方面也无显著差异。
rTMS和TBS在减轻抑郁和焦虑症状方面同样有效,副作用相当。然而,TBS更省时,每次治疗仅持续192秒,对患者来说是一种经济有效的选择。这些发现支持TBS作为TRD的一种实用治疗选择。